Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) EBITDA Margin (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed EBITDA Margin for 11 consecutive years, with 800.89% as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, EBITDA Margin changed N/A year-over-year to 800.89%, compared with a TTM value of 1355.97% through Nov 2024, down 66118.0%, and an annual FY2024 reading of 534.46%, up 37011.0% over the prior year.
  • EBITDA Margin was 800.89% for Q1 2024 at CNBX Pharmaceuticals, down from 199.61% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 103210.29% in Q2 2020 and bottomed at 278365.47% in Q3 2020.
  • Average EBITDA Margin over 4 years is 44891.65%, with a median of 513.68% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 8284669bps in 2020, while the deepest fall reached -59815753bps in 2020.
  • Year by year, EBITDA Margin stood at 278365.47% in 2020, then surged by 99bps to 1812.86% in 2022, then soared by 89bps to 199.61% in 2023, then crashed by -301bps to 800.89% in 2024.
  • Business Quant data shows EBITDA Margin for CNBX at 800.89% in Q1 2024, 199.61% in Q4 2023, and 513.68% in Q3 2023.